Cathy Eng

Cathy Eng, MD
October 15, 2024

Cathy Eng named Vanderbilt-Ingram Cancer Center associate director of Strategic Relations and Research Partnerships 

Her new responsibilities will include promoting clinical research by developing new strategic partnerships with pharmaceutical and biotech companies.

By Tom Wilemon
Cathy Eng, MD
June 21, 2024

International overview of colorectal cancer provides multidisciplinary perspective of clinical advances

The authors hope the report will provide insight on the importance of education, screening and awareness to all health care providers.

By Tom Wilemon
Cathy Eng, MD
April 11, 2024

Cathy Eng to participate in April 15 congressional briefing

Cathy Eng, MD, will participate in a congressional briefing on April 15 focused on “Addressing Representation in Clinical Trials.”

By Tom Wilemon
June 15, 2023

New treatment option for metastatic colorectal cancer prolongs survival

Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.

By Tom Wilemon
March 16, 2023

Eng stresses need for clinical trial support at cancer forum

Vanderbilt’s Cathy Eng, MD, stressed the need for more patient participation and better funding for clinical trials to improve colorectal cancer treatment and outcomes during the White House Cancer Moonshot Colorectal Cancer Forum.

By Tom Wilemon
March 2, 2023

Eng invited to White House Cancer Moonshot forum

Vanderbilt’s Cathy Eng, MD, has been invited to participate in the White House Cancer Moonshot Colorectal Cancer Forum.

By Tom Wilemon
September 13, 2022

Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial

Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.
By Tom Wilemon
August 18, 2022

Abramson, Eng, Johnson named to new VICC roles

Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.
By Tom Wilemon
August 17, 2022

Trial for colorectal cancer drug reaches primary endpoint

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.
By Tom Wilemon
May 6, 2022

Janet Darnell received a lifesaving lung transplant. Five months later she received lifesaving surgery for colon cancer. She calls herself a “walking miracle.”

Without the lung transplant, the cancer may never have been detected.
By Matt Batcheldor
January 25, 2022

Comprehensive framework outlined for addressing early-onset colorectal cancer research

New research from Vanderbilt sets a comprehensive framework for addressing research challenges and patient needs for people under 50 with colorectal cancer.
By Tom Wilemon
September 23, 2021

Eng named co-chair of NCI clinical trials steering committee

Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
By Tom Wilemon
November 18, 2020

New drug for metastatic colorectal cancer enters phase 3 trial

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.
By Tom Wilemon
1 2